A PHP Error was encountered

Severity: Warning

Message: array_shift() expects parameter 1 to be array, null given

Filename: v2_reports/body1.php

Line Number: 106

Backtrace:

File: /home/admin/web/gminsights.com/public_html/application/views/v2_reports/body1.php
Line: 106
Function: array_shift

File: /home/admin/web/gminsights.com/public_html/application/views/v2_layouts/master_header_footer.php
Line: 930
Function: view

File: /home/admin/web/gminsights.com/public_html/application/controllers/Reports.php
Line: 210
Function: view

File: /home/admin/web/gminsights.com/public_html/index.php
Line: 305
Function: require_once

A PHP Error was encountered

Severity: Notice

Message: Undefined variable: table2

Filename: v2_reports/body1.php

Line Number: 107

Backtrace:

File: /home/admin/web/gminsights.com/public_html/application/views/v2_reports/body1.php
Line: 107
Function: _error_handler

File: /home/admin/web/gminsights.com/public_html/application/views/v2_layouts/master_header_footer.php
Line: 930
Function: view

File: /home/admin/web/gminsights.com/public_html/application/controllers/Reports.php
Line: 210
Function: view

File: /home/admin/web/gminsights.com/public_html/index.php
Line: 305
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: v2_reports/body1.php

Line Number: 111

Backtrace:

File: /home/admin/web/gminsights.com/public_html/application/views/v2_reports/body1.php
Line: 111
Function: _error_handler

File: /home/admin/web/gminsights.com/public_html/application/views/v2_layouts/master_header_footer.php
Line: 930
Function: view

File: /home/admin/web/gminsights.com/public_html/application/controllers/Reports.php
Line: 210
Function: view

File: /home/admin/web/gminsights.com/public_html/index.php
Line: 305
Function: require_once

Home > Healthcare & Medical Devices > Active Pharmaceutical Ingredients Market

Active Pharmaceutical Ingredients Market Size By Therapeutic Category (Oncology, Infectious Diseases, Anti-Diabetics, CNS & Anesthesia, Cardiovascular Diseases Biologics), By Synthesis (Chemical Based API, Biological API, Highly Potent API (HPAPI)), By Contract Outsourcing (CDMO, CMO), By Application (Humans, Veterinary), By Drug (Prescription, OTC), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2023 – 2032

  • Report ID: GMI5415
  • Published Date: Jan 2023
  • Report Format: PDF

Industry Statistics

Active Pharmaceutical Ingredients Market size was valued at over USD 228.5 billion in 2022. Driven by the increasing prevalence of chronic diseases, the industry is estimated to expand at more than 6.5% CAGR from 2023 to 2032.
 

Active Pharmaceutical Ingredients Market

Get more details on this report - Request Free Sample PDF
 

Increasing uptake of biopharmaceuticals is anticipated to fuel active pharmaceutical ingredients market progress. The popularity of biopharmaceuticals due to their ability of addressing previously incurable disorders has provided lucrative opportunities for new medications and R&D initiatives focusing on rare diseases. For instance, in 2022, Bluebird Bio, Inc. received FDA approval for its SKYSONA (elivaldogene autotemcel), dedicated to deaccelerating the progression of neurologic dysfunction with individuals suffering from cerebral adrenoleukodystrophy (CALD).
 

Furthermore, rising drug R&D initiatives by public and private players, fueled by growing government investments, are also benefitting the industry outlook. In June 2022, Evonik, specialty chemicals firm, together with the U.S. government, invested over USD 220 million in extending lipid production capacity for mRNA-based therapies in the country.
 

Dynamic pricing policies may restrain industry progression

Unfavorable drug price control policies is a major factor restraining the market development. These policies may appear to be cutting costs and improving access to medications and biopharmaceuticals, but they impact drug producers by slowing both their top and bottom-line growth. Nonetheless, in the coming years, consistent efforts by price regulators are speculated to support in overcoming this issue. Citing an instance, the National Pharmaceutical Pricing Authority of India allowed a 50% price hike for three drugs due to the high prices of APIs in them.
 

Growing prevalence of cancer to push the demand for APIs for oncology

Global Active Pharmaceutical Ingredients Market Share By Therapeutic Category

Get more details on this report - Request Free Sample PDF
 

In terms of therapeutic category, the active pharmaceutical ingredients market is categorized into cardiovascular diseases, biologics, oncology, anti-diabetics, infectious diseases, CNS & anesthesia, and others. The oncology segment held 27% market share in 2022 and is likely to progress at 7.5% CAGR from 2023 to 2032. The increased occurrence of cancer and advancements in medical diagnostics, therapies, and medications created with cutting-edge active pharmaceutical ingredients are fueling the use of APIs for oncology. Novel advancements in the space are as well influencing the segment trends.
 

Favorable investments by CMOs to boost highly potent APIs demand

Global Active Pharmaceutical Ingredients Market Share, By Synthesis, 2022 (%)

Segment

Global market share(%), 2022

Chemical Based API 59%
Biological API 27.7%
Highly Potent API (HPAPI) 13.3%

Get more details on this report - Request Free Sample PDF
 

With respect to synthesis, the active pharmaceutical ingredients market is divided into chemical-based API, biological API, and highly potent API (HPAPI). The HPAPI segment is poised to depict 5.5% CAGR between 2023 and 2032. The high tolerability of HPAPI make them highly preferrable for oral formulations and increasing the life expectancy of cancer patients. Some CMOs are also making continuous investments in large-scale production capacity in countries including India due to the continuing trend of highly potent APIs for drugs.
 

Rising process outsourcing trends to accelerate CMO industry share

Based on contract outsourcing, the active pharmaceutical ingredients market is classified into CDMO and CMO. The CMO (contract manufacturing organization) segment is slated to garner more than USD 263.5 billion revenue by 2032. The growing involvement of international authorities in outsourcing the pharmaceutical production process is accelerating the segment growth. In October 2022, Outsourcing Facilities Association (OFA) inked a settlement agreement with U.S. FDA to accelerate the review of long-pending API contracts for outsourcing facilities for bulk production.
 

Growing trend of online healthcare to proliferate the demand for prescription

From drug point of view, the API market is bifurcated into prescription and OTC. The prescription segment is projected to expand at over 7% CAGR from 2023 to 2032. This is attributed to the growing demand for telehealth and E-prescription API platforms for chronic diseases such as oncology, diabetes, and cardiovascular diseases among others that require a prescription for availing the drug. Rising launch of novel platforms would support the market expansion.
 

Increasing innovations in drugs to boost human segment landscape

In terms of application, the active pharmaceutical ingredients market is segregated into humans and veterinary. The API industry size from human segment is expected to cross USD 381 billion by 2032. The rising number of pharmaceutical R&D initiatives is primed to drive the production of APIs for humans. For instance, in October 2021, Cortex Innovation, a leading key player, unveiled its new API R&D center to improve its drug portfolio in the U.S. Moreover, the development of novel medications that address unmet medical needs is also benefitting research-based pharmaceutical and biotechnology companies.
 

Surging number of API production facilities in Europe to fuel regional market statistics

Global Active Pharmaceutical Ingredients Market Size By Region

Get more details on this report - Request Free Sample PDF
 

Europe active pharmaceutical ingredients market is foreseen to reach over USD 119.5 billion by 2032. The growing trend of new high-tech therapies, development of novel and inventive delivery systems, and the evolution of personalized medications are all contributing to the burgeoning penetration of API manufacturers in the region. For instance, in January 2021, Sanofi, an active pharmaceutical ingredients manufacturer, unveiled EuroAPI, a European standalone API company, to support the rising regional market demand.
 

Growth alliances and mergers to strengthen the active pharmaceutical ingredients industry outlook

Pfizer Inc., Merck & Co. Inc., OfiChem Group, Biocon Ltd., Divi's Laboratories Limited, Procyon Life Sciences, EUROAPI, Teva Pharmaceutical Industries Ltd., Alivira Animal Health Ltd, Cipla Ltd., Aurobindo pharma Ltd., Dr. Reddys Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Neuland Laboratories Ltd.,Solara Active Pharma, Hikal Ltd., SUANFARMA, Qilu Pharmaceutical Co. Ltd,  NGL Fine-Chem Ltd, and Aarti Drugs Ltd., are some of the key participants in the active pharmaceutical ingredients market.
 

These firms are focusing on strategic collaborations and R&D programs to remain ahead in the competitive landscape. For instance, in July 2022, Merck & Co. Inc., an American pharmaceutical company, announced a collaboration deal with Orion, to develop and commercialize ODM-208 active pharmaceutical ingredient and other drugs targeting cytochrome P450 11A1 (CYP11A1) globally. This strategic alliance helped the company in expanding its product portfolio and global presence.
 

COVID-19 pandemic impact on the active pharmaceutical ingredients market trends

The COVID-19 pandemic has had a negative impact on the API industry due to labor shortages, supply chain disruptions, and a lack of raw materials and packaging sources. However, the strong emphasis of governments from across the world on domestic drug production and reducing dependency on exported APIs has proliferated the demand for a variety of pharmaceuticals in the post-pandemic scenario.
 

For instance, in September 2022, Biden Administration inked an executive order to introduce National Biotechnology and Biomanufacturing Initiative. Under this initiative, the U.S. Department of Health and Human Services (HHS) will invest approximately USD 40 million to improve the significance of the biomanufacturing of APIs and other biochemicals.
 

The active pharmaceutical ingredients market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

By Therapeutic Category,

  • Oncology
  • Infectious diseases
  • Anti-diabetics
  • CNS & anesthesia
  • Cardiovascular diseases
  • Biologics
  • Others

By Synthesis,

  • Chemical Based API
  • Biological API
  • Highly Potent API (HPAPI)

By Contract Outsourcing,

  • CDMO
  • CMO

By Application,

  • Humans
  • Veterinary

By Drug,

  • Prescription
  • OTC

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Switzerland
    • France
    • Italy
    • Germany
    • UK
    • Spain
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Vietnam
    • Indonesia
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Chile
    • Peru
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • Bahrain
    • Egypt

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Global market for active pharmaceutical ingredients recorded over USD 228.5 billion valuation in 2022 and is set to progress at more than 6.5% CAGR from 2023 to 2032 owing to rising drug R&D initiatives by public and private players.

Human segment is anticipated to cross USD 381 billion in revenue by 2032 end, due to the rising number of pharmaceutical R&D initiatives and innovation of cutting-edge medications with important clinical advantages.

Prescription segment is poised to expand at over 7% CAGR between 2023 and 2032 as a result of growing demand for medications for chronic diseases such as oncology, diabetes, cardiovascular diseases among others.

Europe APIs market is slated to reach over USD 119.5 billion by 2032 on account of the evolution of personalized medications, development of new high-tech therapies, and inventive delivery systems in the region.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies
Immediate Delivery Available

Premium Report Details

  • Base Year: 2022
  • Companies covered: 20
  • Tables & Figures: 423
  • Countries covered: 28
  • Pages: 295

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount